Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.37
+$0.11 · +4.87%
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Latest quote
$2.37
+$0.11 · +4.87%
After-hours
$2.33
−$0.04 · -1.69%
Oct 8, 7:41 PM ET
Regular session · ET · Market data may be delayed.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Day range
Current $2.37
52-week range
Current $2.37
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
43
Fair Value
Sentiment
50
Mixed
Risk
70
High Risk
Momentum
44
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Day range
Current $2.37
52-week range
Current $2.37
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 9.34M USD | 7.25M USD | 7.62M USD | 6.32M USD | 2.52M USD |
| Selling, general, and administrative | 10.49M USD | 8.11M USD | 8.76M USD | 8.59M USD | 5.21M USD |
| Operating expenses | 19.83M USD | 15.37M USD | 16.38M USD | 14.91M USD | 7.73M USD |
| Interest income | — | — | — | 588.11K USD | 17.72K USD |
| Depreciation and amortization | — | 735 USD | 1.28K USD | 1.78K USD | 1.4K USD |
| Operating income | −19.83M USD | −15.37M USD | −16.38M USD | −14.91M USD | −7.73M USD |
| Net income | −20.85M USD | −15.02M USD | −15.42M USD | −14.32M USD | −7.71M USD |
Company facts updated Oct 9, 2026.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 27, 2025 | 1:28 | — | — |
Stock split | Jul 27, 2021 | 1:4 | — | — |
Stock split | Oct 30, 2020 | 1:20 | — | — |
Effective Jun 27, 2025
1:28
Effective Jul 27, 2021
1:4
Effective Oct 30, 2020
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
